Is Alpelisib-Piqray included in medical insurance?

Alpelisib (Alpelisib) - Piqray is a cancer drug used to treat postmenopausal women and men with breast cancer that is locally advanced or has spread to other parts of the body. Apelix treatment can only be used if the cancer cells have receptors for certain hormones on their surface (HR-positive) and do not have a large amount of another receptor, HER2 (HER2-negative). At this time, the cancer cells must also be proven to have specific mutations (changes) in a gene called "PIK3CA."

Apelvis is given together with the drug fulvestrant (hormone treatment for breast cancer) in patients who have failed hormone therapy alone. In patients whose cancer cells have PIK3CA mutations, an abnormal form of the PI3K enzyme is produced, stimulating the cancer cells to divide and grow in an uncontrolled manner. The active ingredient in alpelisib, alpelisib, works by blocking the activity of abnormal PI3K, thereby reducing the growth and spread of cancer. The most common side effects of Apelvis are increased (less frequently, decreased blood sugar) blood sugar that may require treatment, stomatitis, nausea, vomiting, diarrhea, decreased appetite and weight loss, pancreatitis, rash, anemia, fatigue, hypocalcemia, and alopecia.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.